Top Qs
Timeline
Chat
Perspective
Sirukumab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]
Remove ads
Clinical trials
Rheumatoid arthritis
It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
Research
The drug was previously under development for the treatment of depression.[7]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads